Search results

692 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Quality standards Remove Quality standards filter

Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ozanimod for treating moderate to severe ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

Proposed [GID-TA10740] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Proposed [GID-TA10685] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

Proposed [GID-TA10662] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Proposed [GID-TA10706] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]

Proposed [GID-TA10701] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Proposed [GID-TA10704] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

Proposed [GID-TA10781] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

Proposed
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Integrated health and social care for people experiencing homelessness

In development [GID-NG10170] Expected publication date: 16 March 2022

Type

NICE guideline

Status

In development
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 19 January 2022

Type

NICE guideline

Status

In development
Clostridioides difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 23 July 2021

Type

Antimicrobial prescribing guideline

Status

In development
Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 10 May 2022

Type

NICE guideline

Status

In development
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury

In development [GID-NG10181] Expected publication date: TBC

Type

NICE guideline

Status

In development
Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

Type

NICE guideline

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
Mental wellbeing at work

In development [GID-NG10140] Expected publication date: 15 December 2021

Type

NICE guideline

Status

In development
Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 09 February 2022

Type

NICE guideline

Status

In development
Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 06 April 2022

Type

NICE guideline

Status

In development
Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 10 February 2021

Type

NICE guideline

Status

In development
Looked-after children and young people

In development [GID-NG10121] Expected publication date: 27 September 2021

Type

NICE guideline

Status

In development
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development